9 completed, 6 unknown, 5 active not recruiting, 3 recruiting. 26 Phase 1, 9 Phase 2.
Follow Hypopigmentation: new trials by email Literature Review of Hypopigmentation trials Research Report on Hypopigmentation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Multiple Doses of GR2301 Injection Combined With Phototherapy in Trial Participants With Vitiligo GR2301 injection, Placebo - Vitiligo | Phase 1 / Phase 2 | Not yet recruiting | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 116 | 2026-06-01 | 2026-06-15 |
| Study of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in Vitiligo Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes (hUC-MSC-Exos) Intravenous Infusion, Oral Prednisone, Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes (hUC-MSC-Exos) Local Injection - Vitiligo, Mesenchymal Stem Cells | Phase 1 / Phase 2 | Not yet recruiting | Xijing Hospital | 96 | 2026-04-01 | 2026-04-09 |
| A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo Drug: CGB-600 gel, experimental drug, placebo: gel vehicle - Vitiligo | Phase 1 | Recruiting | CAGE Bio Inc. | 36 | 2025-07-25 | 2026-01-22 |
| A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental Vitiligo FB102, Placebo - Vitiligo | Phase 1 | Active not recruiting | Forte Biosciences, Inc. | 64 | 2025-03-25 | 2026-10-26 |
| Efficacy of Oral Tofacitinib in Combination of Narrow Band UVB in Treatment of Vitiligo Azathioprine, Tofacitinib - Vitiligo | Phase 1 | Active not recruiting | Lahore General Hospital | 20 | 2025-03-01 | 2025-06-29 |
| A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit NN3201 - Gastrointestinal Stromal Tumors, Small-cell Lung Cancer | Phase 1 | Recruiting | Novelty Nobility, Inc. | 67 | 2025-02-03 | 2025-09-23 |
| A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo TEV-53408 - Vitiligo | Phase 1 | Recruiting | Teva Branded Pharmaceutical Products R&D LLC | 66 | 2024-11-11 | 2026-10-29 |
| A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo DR-01 - Alopecia Areata, Vitiligo | Phase 1 | Active not recruiting | Dren Bio | 81 | 2024-10-30 | 2026-07-08 |
| Effectiveness of Omega-3 Poly Unsaturated Fatty Acids on The Treatment of Gingival Hyperpigmentation non surgical with PUFA injection, surgical treatment - Hyperpigmentation, Gingival Hyperpigmentaion | Phase 1 / Phase 2 | Active not recruiting | Suez Canal University | 30 | 2024-01-03 | 2025-07-16 |
| Use of Allogeneic Extracellular Secretomes (EV)Derived From Umbilical Cord Mesenchymal Stromal Cells: a Phase I Open-label Safety Trial. EV - Vitiligo | Phase 1 | Active not recruiting | University of Jordan | 13 | 2023-01-01 | 2025-04-30 |
| Comparitive Study Between Uvb Alone and Uvb With Topical Tacrolimus 0.03% for the Treatment of Vitiligo 0.03% tacrolimus twice daily was applied on group A patients with uvb phototherapy thrice daily - Vitiligo | Phase 1 | Completed | Combined Military Hospital Abbottabad | 60 | 2021-05-01 | 2022-10-17 |
| Effects of Combination Therapy With Camouflage in the Repigmentation of Vitiligo CapulinTM, topical applications and NB-UVB - Vitiligo | Phase 1 | Completed | Peking University People's Hospital | 30 | 2019-08-01 | 2020-07-07 |
| Contribution of Skin Color in Stabilization of Active Cases of Vitiligo by Narrow Band UVB Oral dexamethasone minipulse, Placebo oral tablet - Vitiligo | Phase 1 | Unknown | Ain Shams University | 100 | 2018-11-01 | 2019-07-24 |
| Japanese OMI Treatment With Kit-positive Cells for Enhanced Regeneration Stem cells administered to participants - Chronic Heart Failure, Old Myocardial Infarction | Phase 1 | Unknown | Sakakibara Heart Institute | 6 | 2017-11-15 | 2021-03-18 |
| Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo Tacrolimus 0.03% Ointment, Hydrocortisone Acetate 1% Ointment - Vitiligo, Tacrolimus | Phase 1 / Phase 2 | Unknown | Sohag University | 100 | 2017-10-01 | 2017-11-30 |
| The Effect of Fractional Co2 Laser Either With Tacrolimus, Calcipotriol or NB-UVB in Stable Generalized Vitiligo Tacrolimus ointment, calcipotriol ointment, NB-UVB - Vitiligo Vulgaris | Phase 1 | Unknown | Assiut University | 30 | 2017-08-01 | 2017-08-01 |
| Open-label Pilot Study of Abatacept for the Treatment of Vitiligo Abatacept - Vitiligo | Phase 1 | Unknown | Brigham and Women's Hospital | 10 | 2015-01-01 | 2017-08-09 |
| Nitisinone for Type 1B Oculocutaneous Albinism Nitisinone - Albinism, Vision Loss | Phase 1 / Phase 2 | Completed | National Eye Institute (NEI) | 5 | 2013-04-16 | 2019-02-26 |
| Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV) Afamelanotide, Narrow-Band UVB Light Treatment - Vitiligo | Phase 1 | Completed | Clinuvel Pharmaceuticals Limited | 56 | 2011-06-01 | 2013-03-22 |
| Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo autologous (cellular therapy) - Vitiligo | Phase 1 / Phase 2 | Completed | Centre Hospitalier Universitaire de Nice | 23 | 2011-05-01 | 2014-02-03 |
Showing 20 of 26. Sign in to see all of them.
Vitiligo (21) · Piebaldism (3) · Albinism (2) · Albinism, Oculocutaneous (1) · Alopecia (1) · Alopecia Areata (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Renal Cell (1) · Gastrointestinal Stromal Tumors (1) · Hair Diseases (1) · Hermanski-Pudlak Syndrome (1) · Hyperpigmentation (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Lung Diseases (1)
Pigmentation Disorders (26) · Skin and Connective Tissue Diseases (26) · Skin Diseases (25) · Amino Acid Metabolism, Inborn Errors (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Eye Diseases, Hereditary (5) · Genetic Diseases, Inborn (5) · Metabolism, Inborn Errors (5) · Nutritional and Metabolic Diseases (5) · Skin Diseases, Genetic (5) · Metabolic Diseases (4) · Albinism (3) · Eye Diseases (3) · Pathological Conditions, Signs and Symptoms (3)
Lasers, Gas (2) · Abatacept (1) · Acetylcysteine (1) · Azathioprine (1) · Cell- and Tissue-Based Therapy (1) · Drugs, Investigational (1) · Erythromycin (1) · Fatty Acids, Unsaturated (1) · Ginkgo Extract (1) · Imatinib Mesylate (1) · Infusions, Intravenous (1) · Losartan (1) · Ointments (1) · Phototherapy (1) · Pravastatin (1)
Ain Shams University (1) · Assiut University (1) · Brigham and Women's Hospital (1) · CAGE Bio Inc. (1) · Cairo University (1) · Centre Hospitalier Universitaire de Nice (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Clinuvel Pharmaceuticals Limited (1) · Combined Military Hospital Abbottabad (1) · Dren Bio (1) · Forte Biosciences, Inc. (1) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. (1) · Lahore General Hospital (1) · National Eye Institute (NEI) (1) · National Human Genome Research Institute (NHGRI) (1)
United States (7) · Egypt (3) · Australia (2) · Canada (2) · China (2) · New Zealand (2) · Pakistan (2) · France (1) · Japan (1) · Jordan (1) · Spain (1) · Taiwan (1) · Turkey (Türkiye) (1)
Brian P Brooks, M.D. (1) · Heather Boon, PhD (1) · Henry Lim, MD (1) · Hsin-Su Yu, MD PHD (1) · Juan Du, Doctor (1) · Mahy ElBassiouny, Ass.Lecturer (1) · Michael Rothenberg, MD, PhD (1) · Orest Szczurko, ND MSc(cand) (1) · Philippe Bahadoran, PH (1) · Ramadan Saleh, MD (1) · Sunil Sharma, MD (1) · Thomas Markello, M.D. (1)
PMID 19787413, PMID 21406109, PMID 21451378, PMID 23919018, PMID 25230094, PMID 25596811, PMID 25902042, PMID 30674731, PMID 42046081
2009 (1)